Berapakah harga ABIONYX Pharma S.A. (ABNX)

Harga ABIONYX Pharma S.A. (ABNX) adalah $2.32

Apakah topi pasaran ABIONYX Pharma S.A. (ABNX)

Cap pasaran ABIONYX Pharma S.A. (ABNX) adalah $98.03M

Keuntungan ABIONYX Pharma S.A. (ABNX)

ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.

Tahun	Pendapatan	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Pendapatan

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Pendapatan	Perbezaan Pendapatan	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Moderna, Inc. MRNA.US	$-3.09B	-	US
CSL Limited CSL.AX	$-4.02B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Syarikat

Pendapatan

Perbezaan Pendapatan

Negara